Progressive replacement of human cultured epithelial allografts by recipient cells as evidenced by HLA class I antigens expression.
Human keratinocytes may be grown in vitro into living epithelia devoid of Langerhans cells and MHC class II antigens. These epithelia have been shown to be usable as epidermal allografts in patients with dermal wounds, without any apparent sign of rejection in the 12-month follow-up study. To evidence a progressive replacement by recipient cells of the grafted keratinocytes, we employed anti-MHC class I antigen monoclonal antibodies directed against tissue specificities expressed by either donors or recipients. At 2 and 4 weeks after grafting, some small epithelial cell islets from the recipient phenotype were clearly identified among cells from a donor origin by indirect immunofluorescence. At 6 months, all keratinocytes present at the grafted areas were labelled by antibodies directed toward recipient specificities only. This replacement may be related to the fact that, when placed on such superficial dermal wounds, the allografts are likely colonized by epithelial cells proliferating from residual recipient dermal appendages.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002478:Cells, Cultured; D000078404:Epidermal Cells; D004817:Epidermis / Q000637:transplantation*; D004847:Epithelial Cells; D004848:Epithelium / Q000637:transplantation; D006680:HLA Antigens / Q000235:genetics*; D006801:Humans; D007633:Keratins / Q000276:immunology; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D006680:HLA Antigens; D007633:Keratins